These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2965123)

  • 21. Treatment of skin and soft tissue infections with cefadroxil, a new oral cephalosporin.
    Cordero A
    J Int Med Res; 1976; 4(3):176-8. PubMed ID: 1026545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections.
    Cruciani M; Navarra A; Di Perri G; Andreoni M; Danzi MC; Concia E; Bassetti D
    Clin Infect Dis; 1992 Aug; 15(2):285-9. PubMed ID: 1387805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oritavancin for skin infections.
    Anderson DL
    Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
    Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teicoplanin in the treatment of infection caused by gram-positive organisms.
    Williams AH; Grüneberg RN; Webster A; Ridgway GL
    J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus.
    Pachon J; Prados D; Palomino J; Cantos A; Cisneros JM; Vaquero F
    J Antimicrob Chemother; 1996 Jan; 37(1):197-200. PubMed ID: 8647768
    [No Abstract]   [Full Text] [Related]  

  • 27. Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.
    Perkins RL; Fass RJ; Warner JF; Prior RB; File TM; Tight RR; Gardner WG; Ruiz DE; Slama TG
    J Infect Dis; 1978 May; 137 Suppl():S110-S118. PubMed ID: 418126
    [No Abstract]   [Full Text] [Related]  

  • 28. [Efficacy of teicoplanin in 25 cases of severe infections caused by gram-positive cocci].
    Potel G; Touzé MD; Meignier M; Reynaud A; Baron D
    Pathol Biol (Paris); 1988 May; 36(5):531-5. PubMed ID: 2970058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teicoplanin in infections caused by methicillin-resistant staphylococci.
    Drabu YJ; Walsh B; Blakemore PH; Mehtar S
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():89-92. PubMed ID: 2965136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teicoplanin administration in patients experiencing reactions to vancomycin.
    Smith SR; Cheesbrough JS; Makris M; Davies JM
    J Antimicrob Chemother; 1989 May; 23(5):810-2. PubMed ID: 2527221
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical efficacy and safety of teicoplanin.
    Stille W; Sietzen W; Dieterich HA; Fell JJ
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():69-79. PubMed ID: 2965134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An outbreak of group A streptococcal skin infection: control by source isolation and teicoplanin therapy.
    Webster A; Scott GM; Ridgway GL; Grüneberg RN
    Scand J Infect Dis; 1987; 19(2):205-9. PubMed ID: 2956671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
    Van der Auwera P; Aoun M; Meunier F
    Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and tolerance of teicoplanin in postoperative infections caused by gram-positive microorganisms].
    Alberghina A; Romeo B; Pessione E; Mauri A; Enrichens F; Sciascia C; Olivero G
    Minerva Chir; 1987 Sep; 42(17):1339-45. PubMed ID: 2959879
    [No Abstract]   [Full Text] [Related]  

  • 36. Infections due to gram-positive organisms in children: possible role for teicoplanin.
    Dagan R; Einhorn M; Howard CB; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():37-41. PubMed ID: 1829075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.
    Greenberg RN
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2392-7. PubMed ID: 2150908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Teicoplanin in otorhinolaryngology].
    Cavallo GP; Malcangi A
    G Batteriol Virol Immunol; 1986; 79(7-12):250-7. PubMed ID: 2969345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The international experience with teicoplanin in the treatment of skin and soft tissue infections.
    Chiodo F; Verucchi G; Acuto G
    J Chemother; 1989 Jul; 1(4 Suppl):712-3. PubMed ID: 16312603
    [No Abstract]   [Full Text] [Related]  

  • 40. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.
    Galanakis N; Giamarellou H; Vlachogiannis N; Dendrinos C; Daikos GK
    Eur J Clin Microbiol Infect Dis; 1988 Apr; 7(2):130-4. PubMed ID: 2968907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.